The DOI matches its Crossref record.
Insulin-like Growth Factor Binding Protein-1: Recent Findings and New Directions
Abstract
In 1988, insulin-like growth factor-binding protein-1 (IGFBP-1) became the first characterized member of a group of structurally related soluble proteins which specifically bind and modulate the actions of the IGFs. Since then, a wealth of information has accumulated regarding the physiology of this dynamic serum protein. In this review, we update our 1993 summary (Lee PDK et al. Proc Soc Exp Biol Med 204:4-29) of the status of IGFBP-1 research. The IGFBP-1 protein sequence contains 12 N-terminal and 6 C-terminal cysteine residues which are conserved in other mammalian IGFBP-1 sequences and amongst other IGFBPs; both of the cysteine-rich regions are required for optimal IGF binding. The nonconserved IGFBP-1 midregion may act as both a hinge which defines ligand binding characteristics and as a specific target for protease activity. Integrin-binding and phosphorylation sites within the IGFBP-1 sequence have functional significance in vitro, but their physiologic relevance in vivo have not been defined. The human IGFBP-1 and IGFBP-3 genes are contiguous and located in close proximity to the homeobox A (HOXA) gene cluster on chromosome 7. The other IGFBP genes, located on chromosomes 2, 12, and 17, are also associated with HOX clusters, suggesting evolutionary linkage of the IGFBP and HOX gene families. Similarities between the hlGFBP-1 and phosphoenolpyruvate kinase (PEPCK) promoters, including regions conferring insulin, glucocorticoid, and cyclic adenosine-monophosphate responses, are consistent with our previous hypothesis that IGFBP-1 is involved in regulation of glucose metabolism. The tissue-specific patterns of IGFBP-1 gene expression in liver, kidney, decidua, and ovary may be due to stimulation of IGFBP-1 transcription by hepatic nuclear factor 1 (HNF1) proteins. Clinical and basic studies of IGFBP-1 physiology have been aided by several recently developed assay methods. Numerous investigations have confirmed that insulin, via inhibition of IGFBP-1 transcription, is the primary determinant of IGFBP-1 expression both in vitro and in viva IGF-I and IGF-II also have specific inhibitory effects on IGFBP-1 expression. Glucocorticoids and cAMP stimulate IGFBP-1 transcription, but these effects are observed only in conditions of low or absent insulin effect. Other stimulants of IGFBP-1 expression include thyroid hormones and epidermal growth factor. Phorbol ester stimulation of IGFBP-1 expression can supersede the effects of insulin in vitro; however, the mechanism and in vivo correlates of this effect have not been determined. Cytokines and, perhaps, growth hormones may affect IGFBP-1 expression, perhaps by altering the regulatory actions of insulin; this effect may have important clinical relevance. IGFBP-1 expression is upregulated in liver and (nonhuman) kidney during postinjury regeneration. The IGF-inhibitory actions of IGFBP-1 has been confirmed by numerous in vitro studies and several in vivo animal investigations, including administration of recombinant IGFBP-1 and IGFBP-1 transgenic models. IGFBP-1 has been shown to inhibit somatic linear growth, weight gain, tissue growth, and glucose metabolism. Moreover, IGFBP-1 appears to be a primary determinant of free IGF-I levels in serum. Excess levels of IGFBP-1 may contribute to growth failure in intrauterine growth restriction and in pediatric chronic renal failure, while low IGFBP-1 levels are associated with obesity and with cardiovascular risk factors in insulin resistance syndromes. Serum IGFBP-1 measurements may be useful biochemical marker in these pathologic conditions. IGFBP-1 is expressed in decidualized stromal cells of the uterine endometrium and in ovarian granulosa cells. IGFBP-1, together with IGFs, insulin, ovarian steroids, cytokines, and other factors, is involved in a complex system which regulates menstrual cycles, ovulation, decidualization, blastocyst implantation, and fetal growth. Models for the role of IGFBP-1 in female reproductive physiology are presented, and evidence for pathophysiologic roles in pre-eclampsia, polycystic ovarian syndrome, and uterine malignancy are reviewed. Very recent data indicates that IGFBP-1 undergoes regulated expression in human osteoblasts. Limited information also suggests that IGFBP-1 may be present in peripheral neurons, and that serum IGFBP-1 may increase during exercise and in critical ilIness. In summary, two major roles for IGFBP-1 in normal physiology can be constructed from current data: (i) As an “endocrine” factor, IGFBP-1 regulates the bio-availability of serum IGF-I, thereby modulating IGF-mediated tissue metabolism. The dominant regulation of IGFBP-1 expression by meal-related changes in hepatic insulin concentrations provides a dynamic link to substrate availability. (ii) As an autocrine/paracrine factor, IGFBP-1 appears to play a crucial role in the female reproductive system and, in particular, the sequence of events leading from ovulation to implantation to successful fetal outcom
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Igfbp1 has been proposed as an acute regulator of IGF-1 bioactivity 35 and its elevation in association with HB treatment is unclear.”
From Akt-dependent anabolic activity of natural and synthetic brassinosteroids in rat skeletal muscle cells (2011) · cites this paper as [35]
Citations
Cited by
Sorted by citations
Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression
Yu, H. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.18.1472 · Cited by 1,419
The sirtuin SIRT6 regulates lifespan in male mice
Kanfi, Y., Naiman, S., Amir, G., Peshti, V., Zinman, G., Nahum, L., Bar-Joseph, Z., & Cohen, H. Y. (2012) · Nature · doi:10.1038/nature10815 · Cited by 1,059
Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review.
Kaaks, R., Lukanova, A., & Kurzer, M. S. (2002) · PubMed · Cited by 1,038
The Insulin-Related Ovarian Regulatory System in Health and Disease
Poretsky, L., Cataldo, N. A., Rosenwaks, Z., & Giudice, L. C. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.4.0374 · Cited by 852
Self-citationMcKay, L. I., & Cidlowski, J. A. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.4.0375 · Cited by 805
The biology of white adipocyte proliferation
Hausman, D. B., DiGirolamo, M., Bartness, T. J., Hausman, G., & Martin, R. J. (2001) · Obesity Reviews · doi:10.1046/j.1467-789x.2001.00042.x · Cited by 724
Energy balance and cancer: the role of insulin and insulin-like growth factor-I
Kaaks, R., & Lukanova, A. (2001) · Proceedings of The Nutrition Society · doi:10.1079/pns200070 · Cited by 610
“Also IGFBP-1 has been shown to have important growth regulatory (and anti-tumour) effects in a number of cell types (Lee et al. 1997; Rutanen, 1998).”
BackgroundCoschigano, K. T., Holland, A. N., Riders, M. E., List, E. O., Flyvbjerg, A., & Kopchick, J. J. (2003) · Endocrinology · doi:10.1210/en.2003-0374 · Cited by 510
FoxO1 Regulates Multiple Metabolic Pathways in the Liver
Zhang, W., Patil, S., Chauhan, B., Guo, S., Powell, D. R., Le, J., Klotsas, A., Matika, R. W., Xiao, X., Franks, R. R., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600272200 · Cited by 522
Self-citationSandhu, M. S. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.13.972 · Cited by 495
The Insulin-Like Growth Factor System and Its Pleiotropic Functions in Brain
Russo, V. C., Gluckman, P. D., Feldman, E. L., & Werther, G. A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0024 · Cited by 504
“IGFBP-1 is known to inhibit somatic linear growth, weight gain, tissue growth, and glucose metabolism (293).”
BackgroundSandhu, M. S., Heald, A. H., Gibson, J. M., Cruickshank, J. K., Dunger, D. B., & Wareham, N. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08655-5 · Cited by 470
The Role of Liver-Derived Insulin-Like Growth Factor-I
Ohlsson, C., Mohan, S., Sjögren, K., Tivesten, Å., Isgaard, J., Isaksson, O. G. P., Jansson, J., & Svensson, J. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0010 · Cited by 468
“IGFBP-1, one of the IGFBPs that also may exert IGF-I independent effects (343), increases rapidly after partial hepatectomy (344).”
BackgroundNovel pathways for implantation and establishment and maintenance of pregnancy in mammals
Bazer, F. W., Wu, G., Spencer, T. E., Johnson, G. A., Burghardt, R. C., & Bayless, K. J. (2009) · Molecular Human Reproduction · doi:10.1093/molehr/gap095 · Cited by 390
“…distinct tissue that produces hormones, promotes nutrition of conceptuses, prevents fetal allograft rejection and regulates placentation by limiting Tr invasion through generation of a local cytokine environment which promotes Tr attachment over invasion (Lee et al., 1997; Irwin and Giudice, 1999).”
BackgroundLaughlin, G. A., Barrett-Connor, E., Criqui, M. H., & Kritz-Silverstein, D. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030967 · Cited by 374
Fasting glucose is a risk factor for breast cancer: a prospective study.
Muti, P. C., Quattrin, T., Grant, B. J. B., Krogh, V., Micheli, A., Schünemann, H. J., Ram, M., Freudenheim, J. L., Sieri, S., Trevisan, M., et al. (2002) · PubMed · Cited by 358
Frystyk, J. (2004) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2004.06.001 · Cited by 336
“The rapid and dynamic changes in IGFBP-1 observed in relation to fasting, meal-intake and insulin-induced hypoglycemia [67,222] suggest that this binding protein play an important role as a counter-regulatory agent in glucose homeostasis by adjusting the glucose lowering activity of free IGF-I (and -II) to short-term…”
BackgroundOsteopontin: Roles in Implantation and Placentation1
Johnson, G. A., Burghardt, R. C., Bazer, F. W., & Spencer, T. E. (2003) · Biology of Reproduction · doi:10.1095/biolreprod.103.020651 · Cited by 341
Rimondini, R., Arlinde, C., Sommer, W. H., & Heilig, M. A. (2002) · The FASEB Journal · doi:10.1096/fj.01-0593com · Cited by 320
“tive regulator of IGF-BPs (54); and decreased expression of Ca(2) -ATPase (cytoplasmic Ca(2) pump), which in turn”
BackgroundHomozygous and Heterozygous Expression of a Novel Insulin-Like Growth Factor-I Mutation
Walenkamp, M. J. E., Karperien, M., Pereira, A. M., Hilhorst‐Hofstee, Y., van Doorn, J., Chen, J. W., Mohan, S., Denley, A., Forbes, B. E., van Duyvenvoorde, H. A., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1254 · Cited by 314
Wada, R., Koyama, M., Mizukami, H., Odaka, H., Ikeda, H., & Yagihashi, S. (1999) · Diabetes/Metabolism Research and Reviews · doi:10.1002/(sici)1520-7560(199909/10)15:5 · Cited by 29
Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome
Leo, V. D., Marca, A. L., & Petraglia, F. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0015 · Cited by 291
Wheatcroft, S. B., & Kearney, M. T. (2009) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2009.01.002 · Cited by 276
Environmental Enteric Dysfunction and Growth Failure/Stunting in Global Child Health
Owino, V. O., Ahmed, T., Freemark, M., Kelly, P. M., Loy, A., MANARY, M. J., & Loechl, C. (2016) · PEDIATRICS · doi:10.1542/peds.2016-0641 · Cited by 280
Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor
Rogatsky, I., Wang, J.-C., Derynck, M. K., Nonaka, D. F., Khodabakhsh, D. B., Haqq, C. M., Darimont, B. D., Garabedian, M. J., & Yamamoto, K. R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2336092100 · Cited by 242
The Biological Actions of Dehydroepiandrosterone Involves Multiple Receptors
Webb, S. J., Geoghegan, T. E., Prough, R. A., & Miller, K. K. M. (2006) · Drug Metabolism Reviews · doi:10.1080/03602530600569877 · Cited by 235
“It is one of only a few genes that are negatively regulated by insulin, through a mechanism similar to insulin regulation of the gluconeogenic enzymes phosphoenolpyruvate carboxykinase and glucose6-phosphatase (Suwanichkul et al., 1993; Lee et al., 1997).”
BackgroundInsulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy
Smith, T. J., & Janssen, J. A. M. J. L. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00066 · Cited by 235
Identification and characterization of genes associated with human hepatocellular carcinogenesis.
Kondoh, N., Wakatsuki, T., Ryo, A., Hada, A., Aihara, T., Horiuchi, S., Goseki, N., Matsubara, O., Takenaka, K., Shichita, M., et al. (1999) · PubMed · Cited by 229
Tazuke, S. I., Mazure, N. M., Sugawara, J., Carland, G., Faessen, G. H., Suen, L.-F., Irwin, J. C., Powell, D. R., Giaccia, A. J., & Giudice, L. C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.10188 · Cited by 222
Self-citationAssessment of Cisplatin-Induced Nephrotoxicity by Microarray Technology
Huang, Q. (2001) · Toxicological Sciences · doi:10.1093/toxsci/63.2.196 · Cited by 221
“2), all of which have been associated with kidney remodeling after acute renal failure (Bohe et al. 1998; Gobe et al., 1995; Lee et al., 1997; Leonard et al., 1994; Silkensen et al., 1997).”
BackgroundMynarcik, D. C., McNurlan, M. A., Steigbigel, R. T., Fuhrer, J., & Gelato, M. C. (2000) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200012010-00004 · Cited by 239
Stadtmauer, L., Toma, S. K., Riehl, R. M., & Talbert, L. M. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(00)01766-0 · Cited by 211
Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system
Kurita, T., Wang, Y. Z., Donjacour, A. A., Zhao, C., Lydon, J. P., O’Malley, B. W., Isaacs, J. T., Dahiya, R., & Cunha, G. R. (2001) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400797 · Cited by 203
“41 IGF signaling plays a role in growth and survival of prostatic(42) and uterine(43) epithelia, and IGFBPs antagonize IGF signaling.(44) Thus, IGFBPs are possible mediators of stromal-epithelial interactions in prostatic and uterine epithelial apoptosis.”
BackgroundHeald, A. H., Cruickshank, J. K., Riste, L., Cade, J. E., Anderson, S. G., Greenhalgh, A., Sampayo, J. N., Taylor, W., Fraser, W. D., White, A. E., et al. (2001) · Diabetologia · doi:10.1007/s001250051623 · Cited by 189
Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in immunity and inflammation
Heemskerk, V. H., Daemen, M. A. R. C., & Buurman, W. A. (1999) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(98)00022-7 · Cited by 182
Boyd, D. B. (2003) · Integrative Cancer Therapies · doi:10.1177/1534735403259152 · Cited by 188
“PI3K-Akt signaling is involved in anchorage-independent cell growth61 and cell cycle entry at the G1/S transition62 and is an important survival signal inhibiting apoptosis.54,63 In addition to the direct effects of insulin at the IR, insulin inhibits hepatic synthesis of both IGFBP-1 and IGFBP-2, leading to an increa…”
BackgroundHaywood, N. J., Slater, T. A., Matthews, C., & Wheatcroft, S. B. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.10.008 · Cited by 179
Acanthosis Nigricans Associated with Insulin Resistance
Hermanns‐Lê, T., Scheen, A., & rard, G. R. E. P. (2004) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200405030-00008 · Cited by 162
Coen, M., Ruepp, S. U., Lindon, J. C., Nicholson, J. K., Pognan, F., Lenz, E. M., & Wilson, I. D. (2004) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2003.12.019 · Cited by 164
Serum levels of total and free IGF-I and IGFBP-3 are increased and maintained in long-term training
Koziris, L. P., Hickson, R. C., Chatterton, R. T., Groseth, R. T., Christie, J. M., Goldflies, D. G., & Unterman, T. G. (1999) · Journal of Applied Physiology · doi:10.1152/jappl.1999.86.4.1436 · Cited by 157
“IGF-I also circulates bound to lower-molecular-weight IGFBPs, including IGFBP-1, a 30-kDa protein, which is produced largely in the liver and is thought to be the major short-term modulator of IGF-I bioavailability (23).”
BackgroundDiabetes and ethnic minorities
Oldroyd, J. C., Banerjee, M., Heald, A. H., & Cruickshank, K. J. (2005) · Postgraduate Medical Journal · doi:10.1136/pgmj.2004.029124 · Cited by 162
Dossus, L., Lukanova, A., Rinaldi, S., Allen, N. E., Cust, A. E., Becker, S., Tjønneland, A. M., Hansen, L., Overvad, K., Chabbert‐Buffet, N., et al. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws309 · Cited by 154
Implantation: Embryonic Signals and the Modulation of the Uterine Environment—A Review
Fazleabas, A. T., Kim, J., & Straková, Z. (2004) · Placenta · doi:10.1016/j.placenta.2004.01.014 · Cited by 145
“Its proposed roles in reproductive physiology and pathology are numerous ([46]; reviewed by Fowler et al.”
BackgroundInfluentialFKHR Binds the Insulin Response Element in the Insulin-Like Growth Factor Binding Protein-1 Promoter
Durham, S. K., Suwanichkul, A., Scheimann, A. O., Yee, D., Jackson, J. G., Barr, F. G., & Powell, D. R. (1999) · Endocrinology · doi:10.1210/endo.140.7.6856 · Cited by 146
“The ability of FKHR to stimulate production of IGFBP-1, a protein which blocks IGF-mediated growth and substrate utilization in vivo (1), is consistent with the ability of the FKHR homologue DAF-16 to slow growth and shift metabolism away from energy utilization in C.”
BackgroundSchoen, R. E., Weissfeld, J. L., Kuller, L. H., Thaete, F. L., EVANS, R., Hayes, R. B., & Rosen, C. J. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.05.051 · Cited by 155
Regulation of Insulin-Like Growth Factor Binding Protein-1 during Protracted Critical Illness
Mesotten, D., Delhanty, P. J. D., Vanderhoydonc, F., Hardman, K. V., Weekers, F., Baxter, R. C., & den Berghe, G. V. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020664 · Cited by 142
“The two dominant metabolic influences on IGFBP-1 gene expression appear to be insulin, which is suppressive, and the availability of hepatic substrate, with IGFBP-1 stimulated by substrate deprivation (7).”
BackgroundKunnari, A., Ukkola, O. H., Päivänsalo, M. J., & Kesäniemi, Y. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2115 · Cited by 138
Kalmijn, S., Janssen, J. A. M. J. L., Pols, H. A. P., Lamberts, S. W. J., & Breteler, M. M. B. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.12.7033 · Cited by 140
Arslanian, S. A., Bacha, F., Saad, R., & Gungor, N. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.115 · Cited by 138
“There is convincing evidence that IGFBP-1 plays an integral role in glucoregulation (31).”
BackgroundLeu, J. I., Crissey, M. A. S., Leu, J. P., Ciliberto, G., & Taub, R. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.2.414-424.2001 · Cited by 134
Rajwani, A., Ezzat, V., Smith, J., Yuldasheva, N. Y., Duncan, E. R., Gage, M., Cubbon, R. M., Kahn, M., Imrie, H., Abbas, A., et al. (2012) · Diabetes · doi:10.2337/db11-0963 · Cited by 135
“Although the receptor for IGFBP1 (6) and the proximal signaling intermediaries are yet to be identified, IGFBP1stimulated NO production is also mediated through the PI3K/Akt pathway, culminating in phosphorylation of eNOS (7) and an increase in NOS activity.”
BackgroundIGF-1, the Cross Road of the Nutritional, Inflammatory and Hormonal Pathways to Frailty
Maggio, M. G., Vita, F. D., Lauretani, F., Buttò, V., Bondi, G., Cattabiani, C., Nouvenne, A., Meschi, T., Dall’Aglio, E., & Ceda, G. P. (2013) · Nutrients · doi:10.3390/nu5104184 · Cited by 144
“IGF-1 bioactivity and bioavailability are influenced by six binding proteins (IGFBPs), which also have independent biological actions [12].”
BackgroundRobinson, R. S., Mann, G. E., Gadd, T., et al. (2000) · Journal of Endocrinology · doi:10.1677/joe.0.1650231 · Cited by 135
“Since high endometrial IGFBP-1 levels are observed when progesterone levels are high and the human IGFBP-1 gene contains a progesterone response element, it has been suggested that progesterone regulates IGFBP-1 expression in the endometrium (Lee et al. 1997, Tseng et al. 1997).”
BackgroundPrediction of Nephrotoxicant Action and Identification of Candidate Toxicity-Related Biomarkers
Thukral, S. K., Nordone, P. J., Hu, R., Sullivan, L., Galambos, E., Fitzpatrick, V. D., Healy, L. N., Bass, M. B., Cosenza, M. E., & Afshari, C. A. (2005) · Toxicologic Pathology · doi:10.1080/01926230590927230 · Cited by 132
“Additional genes associated with tissue remodeling included osteopontin, TIMP1, IGFBP1, all of which have been associated with kidney remodeling following acute renal failure (Eddy and Giachelli, 1995; Lee et al., 1997; Bohe et al., 1998; Persy et al., 1999; Huang et al., 2001).”
BackgroundGrowth hormone/insulin-like growth factor system in children with chronic renal failure
T�nshoff, B., Kiepe, D., & Ciarmatori, S. (2005) · Pediatric Nephrology · doi:10.1007/s00467-005-1821-0 · Cited by 130
Transgenic mouse models for studying the functions of insulin‐like growth factor‐binding proteins
Schneider, M. R., Lahm, H., Wu, M., Hoeflich, A., & Wolf, E. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.5.629 · Cited by 128
“Likewise, IGFBP-1 is involved in intrauterine growth regulation in humans (49) and rodents (75, 76).”
BackgroundTidermark, J., Ponzer, S., Carlsson, P., Söderqvist, A., Brismar, K., Tengstrand, B., & Cederholm, T. (2004) · Clinical Nutrition · doi:10.1016/j.clnu.2003.10.006 · Cited by 127
Structure, Developmental Expression, and Physiological Regulation of Zebrafish IGF Binding Protein-1
Maures, T. J., & Duan, C. (2002) · Endocrinology · doi:10.1210/endo.143.7.8905 · Cited by 128
Kelley, K. M., Haigwood, J. T., Pérez, M. E. M., et al. (2001) · Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology · doi:10.1016/s1096-4959(01)00314-1 · Cited by 123
de Groof, F., Joosten, K. F. M., Janssen, J. A. M. J. L., de Kleijn, E. D., Hazelzet, J. A., Hop, W. C. J., Uitterlinden, P., van Doorn, J., & Hokken‐Koelega, A. C. S. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.7.8605 · Cited by 122
“Normally, circulating IGFBP-1 is mainly regulated by insulin through inhibition of gene transcription in the liver, constituting a major determinant of free IGF-I availability (32, 33).”
Yeagley, D., Guo, S., Unterman, T. G., & Quinn, P. G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101215200 · Cited by 117
Euglycemic hyperinsulinemia augments the cytokine and endocrine responses to endotoxin in humans
Soop, M., Duxbury, H., Agwunobi, A. O., Gibson, M., Hopkins, S. J., Childs, C., Cooper, R. G., Maycock, P. F., Little, R. A., & Carlson, G. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00535.2001 · Cited by 119
Zucchi, S., Blüthgen, N., Ieronimo, A., & Fent, K. (2011) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2010.10.001 · Cited by 121
“(2000) demonstrated that oral administration of estradiol increases circulating levels of IGFBP-1, and it is also up-regulatedduring catabolic states, such as insulin-dependent diabetes mellitus and after stress conditions in mammals and fish (Lee et al., 1997; Kelley et al., 2001).”
BackgroundDuplication and Diversification of the Hypoxia-Inducible IGFBP-1 Gene in Zebrafish
Kamei, H., Lu, L., Jiao, S., Li, Y., Gyrup, C., Laursen, L. S., Oxvig, C., Zhou, J., & Duan, C. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003091 · Cited by 112
“In the L-domain of mammalian IGFBP-1, there is a proline, glutamine, serine, and threonine (PEST) motif, known to contribute to its susceptibility to proteolysis [15].”
Leu, J. I.-J., Crissey, M. A. S., & Taub, R. A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16712 · Cited by 129
Macqueen, D. J., de la serrana, D. G., & Johnston, I. A. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst017 · Cited by 114
“…al. 2002, 2006; Ren et al. 2008), whereas IGFBP-1 and -2 generally inhibit the growth-promoting functions of IGF in both mammals and fish (Gockerman et al. 1995; Lee et al. 1997; Duan et al. 1999; Firth and Baxter 2002; Kiepe et al. 2002; Kajimura et al. 2005; Zhou et al. 2008; Kamei et al. 2008).”
HOX gene network is involved in the transcriptional regulation of in vivo human adipogenesis
Cantile, M., Procino, A., D'Armiento, M. R., Cindolo, L., & Cillo, C. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10210 · Cited by 111
Monsalve, M., & Olmos, Y. (2011) · Current Drug Targets · doi:10.2174/138945011796150307 · Cited by 113
“differentiation both in vitro [298] and in vivo [299, 300] and is thought to play a role during blastocyst implantation [295].”
BackgroundZhao, H.-L., Sui, Y., Qiao, C., Yip, K. Y.-L., Leung, R. K. K., Tsui, S. K., Lee, H.-M., Wong, H. K. T., Zhu, X., Siu, J. J., et al. (2012) · Diabetes · doi:10.2337/db11-1164 · Cited by 110
“The insulin/IGF-I/IGFBP pathway constitutes a complex network to modulate energy metabolism and cellular growth (31), in part mediated through the PI3K/Akt/mammalian target of rapamycin pathway (32–34).”
PCOS and Depression: Common Links and Potential Targets
Kolhe, J. V., Chhipa, A. S., Butani, S., Chavda, V. K., & Patel, S. S. (2021) · Reproductive Sciences · doi:10.1007/s43032-021-00765-2 · Cited by 126
Insulin-Like Growth Factor-Binding Proteins of Teleost Fishes
de la serrana, D. G., & Macqueen, D. J. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00080 · Cited by 110
Leu, J. I.-J., Crissey, M. A. S., Craig, L. E., & Taub, R. A. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.4.1251-1259.2003 · Cited by 108
Frystyk, J., Ivarsen, P., Skjærbæk, C. B., et al. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00798.x · Cited by 108
Elevated Serum Levels of Free Insulin-Like Growth Factor I in Polycystic Ovary Syndrome1
van Dessel, H. J. H. M., Lee, P., Faessen, G. H., Fauser, B. C. J. M., & Giudice, L. C. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.9.5941 · Cited by 108
Self-citationLeu, J. I.-J., Crissey, M. A. S., & Taub, R. A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200316712 · Cited by 108
Developmental response to hypoxia
Huang, S.-T. J., Vo, K. C., Lyell, D. J., Faessen, G. H., Tulac, S., Tibshirani, R. J., Giaccia, A. J., & Giudice, L. C. (2004) · The FASEB Journal · doi:10.1096/fj.03-1377com · Cited by 104
“minute availability of free IGF-I in the circulation (6, 7).”
BackgroundSelf-citationKim, J. J., Taylor, H. S., Akbas, G. E., Foucher, I., Trembleau, A., Jaffe, R. C., Fazleabas, A. T., & Unterman, T. G. (2003) · Biology of Reproduction · doi:10.1095/biolreprod.102.009316 · Cited by 106
“Insulin-like growth factor binding protein-1 (IGFBP-1) is expressed primarily in the liver, kidney, decidualized endometrium, and luteinizing granulosa cells [1].”
BackgroundKim, S. T., & Moley, K. H. (2008) · Reproduction · doi:10.1530/rep-08-0167 · Cited by 107
“Oxidation of lipids, proteins, and other macromolecules such as DNA occurs during the development of diabetes (Ohkawa et al. 1979), and mitochondrial DNA mutations have also been reported in diabetic tissues, suggesting oxidative stress-related mitochondrial damage (Lee et al. 1997).”
BackgroundThe Role of Endocrine Insulin-Like Growth Factor-I and Insulin in Breast Cancer
Lann, D. E., & LeRoith, D. (2008) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-008-9100-x · Cited by 104
“Hyperinsulinemia, the hallmark of type 2 diabetes, can lead to the repression of IGFBP-1 hepatic production and therefore decreased release into circulation [80, 81].”
BackgroundCust, A. E., Allen, N. E., Rinaldi, S., Dossus, L., Friedenreich, C. M., Olsen, A., Tjønneland, A. M., Overvad, K., Clavel‐Chapelon, F., Boutron‐Ruault, M., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22578 · Cited by 101
“Lower IGFBP-1 and IGFBP-2 levels may lead to increased IGF-I bioavailability in the circulation and endometrial tissue,(2,11,13,41,43) because contrary to IGFBP-3, IGFBP-1 and IGFBP-2 can combine with IGF-I to form a small complex that can cross the capillary endothelium and prevent IGF-I receptor binding.(11,12,14,40…”
BackgroundResultChanges in the circulating IGF system during short-term fasting and refeeding in rats
Frystyk, J., Delhanty, P. J. D., Skjærbæk, C., et al. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.277.2.e245 · Cited by 102
“In fact, because the liver is the primary source of circulating IGFBP-1, serum IGFBP-1 has been suggested to reflect portal rather than peripheral insulin levels (3, 15).”
BackgroundInfluentialNayak, N. R., & Giudice, L. C. (2003) · Placenta · doi:10.1053/plac.2002.0906 · Cited by 101
Self-citationColao, A., Somma, C. D., Cascella, T., Pivonello, R., Vitale, G., Grasso, L. F. S., Lombardi, G., & Savastano, S. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0201 · Cited by 101
Leu, J. I.-J., & George, D. L. (2007) · Genes & Development · doi:10.1101/gad.1567107 · Cited by 102
“However, many recent studies have documented that these IGFBP proteins also have important intracellular functions that are independent of, and unrelated to, their secretion and interactions with the IGFs (Lee et al. 1997; Duan and Xu 2005).”
BackgroundInfluentialPerluigi, M., di Domenico, F., Fiorini, A., Cocciolo, A., Giorgi, A., Foppoli, C., Butterfield, D. A., Giorlandino, M., Giorlandino, C., Eugenia Schininà, M., et al. (2011) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201000121 · Cited by 97
“IGFBP-1 regulates minute-to-minute bioavailability of IGFs in the circulation and inhibits IGF actions [50].”
BackgroundGiudice, L. C., Mark, S., & Irwin, J. C. (1998) · Journal of Reproductive Immunology · doi:10.1016/s0165-0378(98)00018-7 · Cited by 97
Self-citationShimizu, M., & Dickhoff, W. W. (2017) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2017.08.002 · Cited by 95
“Circulating levels of IGFBP-1 are generally inversely related to those of insulin after meals, and insulin treatment inhibits IGFBP-1 both at the mRNA and protein levels (Lee et al., 1993, 1997).”
BackgroundEzzat, V., Duncan, E. R., Wheatcroft, S. B., & Kearney, M. T. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00709.x · Cited by 91
Peterson, B. C., & Small, B. C. (2003) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2003.10.005 · Cited by 93
“IGFBP-1 has been shown to inhibit IGF actions in numerous in vitro and in vivo animal studies [34].”
BackgroundInfluentialInfluence of Nutrition on Responses to Resistance Training
VOLEK, J. S. (2004) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000121944.19275.c4 · Cited by 93
“may contribute to glucose regulation by countering the insulin-like, hypoglycemic effects of free IGF-I (40).”
BackgroundKrapina 1: A juvenile Neandertal from the early late Pleistocene of Croatia
Minugh‐Purvis, N., Radovčić, J., & Smith, F. H. (2000) · American Journal of Physical Anthropology · doi:10.1002/(sici)1096-8644(200003)111:3 · Cited by 41
Larsson, S. C., Spyrou, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155326 · Cited by 89
Effects of exogenous cortisol on the GH/IGF-I/IGFBP network in channel catfish
Peterson, B. C., & Small, B. C. (2005) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2005.01.003 · Cited by 91
“In addition, the IGFBP-1 gene possesses glucocorticoid-response elements, and the steroid can potentially increase IGFBP-1 levels [50].”
Epidemiology of Endometrial Carcinoma: Etiologic Importance of Hormonal and Metabolic Influences
Felix, A. S., Yang, H., Bell, D. W., & Sherman, M. E. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-43139-0_1 · Cited by 97
Effects of Weight Control and Physical Activity in Cancer Prevention
Kaaks, R., & Lukanova, A. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04118.x · Cited by 89
Ngo, T. H., Barnard, R. J., Cohen, P., Freedland, S. J., Tran, C., DeGregorio, F., Elshimali, Y., Heber, D., & Aronson, W. J. (2003) · PubMed · Cited by 89
IGF-I, IgA, and IgG responses to bovine colostrum supplementation during training
Mero, A. A., Kähkönen, J., Nykänen, T., Parviainen, T., Jokinen, I. E., Takala, T., Nikula, T. K., Rasi, S., & Leppäluoto, J. (2002) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00002.2002 · Cited by 88
Shimizu, M., Cooper, K. A., Dickhoff, W. W., et al. (2009) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.90939.2008 · Cited by 88
“The levels of free IGF-I are presumably regulated in part by short-term changes in IGFBP-1 (13, 22).”
BackgroundInfluentialRahmani, J., Kord‐Varkaneh, H., Clark, C. C. T., Zand, H., Bawadi, H. A., Ryan, P. M., Fatahi, S., & Zhang, Y. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100910 · Cited by 96
Nonvillous Parts and Trophoblast Invasion
Frank, H., & Kaufmann, P. (2000) · Springer eBooks · doi:10.1007/978-1-4757-4199-5_9 · Cited by 87
Metadata
- Authors
- Lee, P. D. K., Giudice, L. C., Conover, C. A., & Powell, D. R.
- Affiliations
- Mayo Clinic (US)
- Venue
- Experimental Biology and Medicine
- Publisher
- Frontiers Media SA
- Published
- 1997-12-01
- Volume
- 216
- Issue
- 3
- Pages
- 319-357
- ISSN
- 0071-3384 (ISSN-L)
- 1535-3702
- 1535-3699
- OpenAlex
- W2036466897
- Cited by
- 523
- References
- 0
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 8 · 2023: 4 · 2022: 6 · 2021: 10 · 2020: 8 · 2019: 11 · 2018: 10 · 2017: 19 · 2016: 16 · 2015: 16 · 2014: 11 · 2013: 17 · 2012: 14
- FWCI
- 16.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Experimental Biology and Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- IGFBP-1, insulin-like growth factor, IGF binding, cysteine-rich region, protease cleavage, integrin binding, phosphorylation sites, IGFBP-3, chromosome 7, glucose metabolism, glucocorticoids, cyclic AMP, tissue-specific gene expression
- MeSH terms
- Amino Acid Sequence, Animals, Bone and Bones, Cartilage, Connective Tissue, Female, Gene Expression Regulation, Genitalia, Female, Genitalia, Male, Humans, Kidney, Liver, Male, Molecular Sequence Data, Organ Specificity, Substrate Specificity, Insulin-Like Growth Factor Binding Protein 1, Evolution, Molecular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review